Reduced irisin levels in patients with acromegaly.

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Hormone Molecular Biology and Clinical Investigation Pub Date : 2022-07-19 eCollection Date: 2022-09-01 DOI:10.1515/hmbci-2022-0009

Suleyman Nahit Sendur, Gokhan Baykal, Busra Firlatan, Busra Aydin, Incilay Lay, Selcuk Dagdelen, Mehmet Alikasifoglu, Tomris Erbas

{"title":"Reduced irisin levels in patients with acromegaly.","authors":"Suleyman Nahit Sendur, Gokhan Baykal, Busra Firlatan, Busra Aydin, Incilay Lay, Selcuk Dagdelen, Mehmet Alikasifoglu, Tomris Erbas","doi":"10.1515/hmbci-2022-0009","DOIUrl":null,"url":null,"abstract":"Objectives: Several metabolic disturbances are seen in acromegaly however, data regarding the contribution of irisin to these disturbances is currently insufficient. In a cohort of patients with acromegaly, we measured serum irisin levels in active and controlled cases and determined independent factors that effect serum irisin including fibronectin type III domain-containing protein 5 (FNDC5) genotyping.Methods: A cross-sectional case-control study including 46 patients with acromegaly (28 F/18 M, age: 50.3 ± 12.1 year, BMI: 30.7 ± 5.1 kg/m2) and 81 age-, gender-, body mass index- and body composition-matched healthy controls was conducted. 15 acromegalic patients (33%) had active disease. Irisin levels were measured by enzyme-linked immunosorbent assay. Three different regions (rs3480, rs1746661, and rs16835198) of FNDC5 were subjected to polymorphism analyses.Results: Both groups were overweight and had similar body composition. Irisin levels were lower in patients with acromegaly than controls (median [IQR]: 44.8 [41.7-46.7] ng/mL vs. 51.7 [45.5-60.1] ng/mL, p≤0.001, respectively). Active and controlled patients had similar irisin levels. Irisin was not correlated with growth hormone (GH), insulin-like growth factor 1 (IGF-1), and IGF-1 index. In multiple linear regression model, somatostatin receptor ligand use (β=-20.30, 95% CI [-34]-[-6], p=0.006) was determined as the only independent factor that affect serum irisin.Conclusions: Serum irisin levels are low in patients with acromegaly who are on somatostatin receptor ligand therapy. Single nucleotide polymorphisms (SNPs) of FNDC5 have no independent effects on circulating irisin levels under somatostatin ligand action. Endocrine muscle functions also seem to be regulated by somatostatin action, which requires further studies.","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2022-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Several metabolic disturbances are seen in acromegaly however, data regarding the contribution of irisin to these disturbances is currently insufficient. In a cohort of patients with acromegaly, we measured serum irisin levels in active and controlled cases and determined independent factors that effect serum irisin including fibronectin type III domain-containing protein 5 (FNDC5) genotyping.

Methods: A cross-sectional case-control study including 46 patients with acromegaly (28 F/18 M, age: 50.3 ± 12.1 year, BMI: 30.7 ± 5.1 kg/m²) and 81 age-, gender-, body mass index- and body composition-matched healthy controls was conducted. 15 acromegalic patients (33%) had active disease. Irisin levels were measured by enzyme-linked immunosorbent assay. Three different regions (rs3480, rs1746661, and rs16835198) of FNDC5 were subjected to polymorphism analyses.

Results: Both groups were overweight and had similar body composition. Irisin levels were lower in patients with acromegaly than controls (median [IQR]: 44.8 [41.7-46.7] ng/mL vs. 51.7 [45.5-60.1] ng/mL, p≤0.001, respectively). Active and controlled patients had similar irisin levels. Irisin was not correlated with growth hormone (GH), insulin-like growth factor 1 (IGF-1), and IGF-1 index. In multiple linear regression model, somatostatin receptor ligand use (β=-20.30, 95% CI [-34]-[-6], p=0.006) was determined as the only independent factor that affect serum irisin.

Conclusions: Serum irisin levels are low in patients with acromegaly who are on somatostatin receptor ligand therapy. Single nucleotide polymorphisms (SNPs) of FNDC5 have no independent effects on circulating irisin levels under somatostatin ligand action. Endocrine muscle functions also seem to be regulated by somatostatin action, which requires further studies.

查看原文本刊更多论文

肢端肥大症患者鸢尾素水平降低。

目的:肢端肥大症中有几种代谢紊乱，然而，鸢尾素在这些紊乱中的作用目前还不充分。在一组肢端肥大症患者中，我们测量了活跃病例和对照病例的血清鸢尾素水平，并确定了影响血清鸢尾素的独立因素，包括纤维连接蛋白III型结构域含蛋白5 (FNDC5)基因分型。方法:采用横断面病例对照研究，纳入46例肢端肥大症患者(28 F/18 M，年龄:50.3±12.1岁，BMI: 30.7±5.1 kg/m2)和81例年龄、性别、体质指数和身体成分匹配的健康对照。肢端肥大症患者15例(33%)有活动性疾病。采用酶联免疫吸附法测定鸢尾素水平。对FNDC5的3个不同区域(rs3480、rs1746661和rs16835198)进行多态性分析。结果:两组均超重，体成分相似。肢端肥大症患者的鸢尾素水平低于对照组(中位数[IQR]: 44.8 [41.7-46.7] ng/mL vs. 51.7 [45.5-60.1] ng/mL, p≤0.001)。活跃组和对照组患者的鸢尾素水平相似。鸢尾素与生长激素(GH)、胰岛素样生长因子1 (IGF-1)及IGF-1指数无相关性。在多元线性回归模型中，生长抑素受体配体的使用(β=-20.30, 95% CI [-34]-[-6]， p=0.006)是影响血清鸢尾素的唯一独立因素。结论:肢端肥大症患者在接受生长抑素受体配体治疗时血清鸢尾素水平较低。FNDC5的单核苷酸多态性(snp)在生长抑素配体作用下对循环鸢尾素水平无独立影响。肌肉内分泌功能似乎也受生长抑素作用的调节，这需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.